Stock 1541 IMMUNEONCO BIOPHARMACEUTICALS (SHANGHAI) INC.
Add to a list
To use this feature you must be a member
Log inSign up

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. Stock

Equities

1541

CNE100006624

Biotechnology & Medical Research

Delayed Hong Kong S.E.
Other stock markets
 09:48:17 2024-05-26 pm EDT 		5-day change 1st Jan Change
14.82 HKD +1.51% Intraday chart for ImmuneOnco Biopharmaceuticals (Shanghai) Inc. +0.27% -50.43%
May. 17 Immuneonco Biopharmaceuticals Gets Regulatory Go-Ahead for Phase 3 Trial of Myelodysplastic Syndrome Drug in China MT
May. 17 Immuneonco Biopharmaceuticals Inc. Receives Approval from the Center for Drug Evaluation of the National Medical Products Administration of the People's Republic of China for A Randomized, Double-Blind, Controlled Phase III Clinical Trial of MM01 (Timdarpacept) in Combination with Azacitidine for the First-Line Treatment of Higher-Risk Myelodysplastic Syndrome (HR MDS) CI

Financials

Sales 2024 * 588K 81.26K 635K Sales 2025 * 745K 103K 804K Capitalization 5.06B 699M 5.46B
Net income 2024 * - Net income 2025 * - EV / Sales 2024 * 7,765 x
Net cash position 2024 * 494M 68.2M 533M Net cash position 2025 * 547M 75.48M 590M EV / Sales 2025 * 6,062 x
P/E ratio 2024 *
-
P/E ratio 2025 *
-
Employees 145
Yield 2024 *
-
Yield 2025 *
-
Free-Float 18.61%
More Fundamentals * Assessed data

Chart ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Dynamic Chart

Latest news about ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Immuneonco Biopharmaceuticals Gets Regulatory Go-Ahead for Phase 3 Trial of Myelodysplastic Syndrome Drug in China MT
Immuneonco Biopharmaceuticals Inc. Receives Approval from the Center for Drug Evaluation of the National Medical Products Administration of the People's Republic of China for A Randomized, Double-Blind, Controlled Phase III Clinical Trial of MM01 (Timdarpacept) in Combination with Azacitidine for the First-Line Treatment of Higher-Risk Myelodysplastic Syndrome (HR MDS) CI
ImmuneOnco Obtains Chinese Nod for Phase III Trials of Anti-Cancer Medication MT
ImmuneOnco Biopharmaceuticals Inc. Receives Approval from the National Medical Products Administration of the People's Republic of China for the Protocol of the Phase Iii Clinical Trial of IMM01 CI
Immuneonco Biopharmaceuticals' 2023 Loss Narrows as Other Income Increases MT
ImmuneOnco Biopharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Immuneonco Biopharmaceuticals CFO Resigns MT
Immuneonco Biopharmaceuticals Inc. Announces Board and Executive Changes CI
ImmuneOnco Begins Phase II Clinical Trial of Anti-Tumor Drug MT
ImmuneOnco Biopharmaceuticals Inc. Announces First Patient Dosed in the Phase II Clinical Trial of IMM2510 for the Treatment of Refractory or Relapsed Alveolar Soft Part Sarcoma CI
ImmuneOnco Biopharmaceuticals Gets US FDA's Orphan-Drug Designation for Leukemia Drug Combination MT
ImmuneOnco Biopharmaceuticals Gets Nod to Trial Cancer Drug MT
ImmuneOnco Biopharmaceuticals Inc. Receives an Investigational New Drug Approval from the National Medical Products Administration of the People's Republic of China CI
ImmuneOnco to Present Results of Anti-Cancer Drug Studies at American Convention MT
China Grants Investigational New Drug Approval to ImmuneOnco's Cancer Treatment; Shares Fall 4% MT
More news

Quotes and Performance

1 day+1.51%
1 week+0.27%
Current month-2.63%
1 month-2.24%
3 months-38.12%
6 months-48.90%
Current year-50.43%
More quotes

Highs and lows

1 week
13.96
Extreme 13.96
17.02
1 month
13.96
Extreme 13.96
17.02
Current year
13.58
Extreme 13.58
30.40
1 year
13.58
Extreme 13.58
32.15
3 years
13.58
Extreme 13.58
32.15
5 years
13.58
Extreme 13.58
32.15
10 years
13.58
Extreme 13.58
32.15
More quotes

Managers and Directors - ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Managers TitleAgeSince
Wen Zhi Tian CEO
 Chief Executive Officer - 15-05-31
Qi Ying Lu CTO
 Chief Tech/Sci/R&D Officer - 22-02-28
Song Li CTO
 Chief Tech/Sci/R&D Officer - 15-11-30
Members of the board TitleAgeSince
Chi Tat Yeung BRD
 Director/Board Member 55 22-05-31
Zhi Hua Yu BRD
 Director/Board Member 56 -
Wen Zhi Tian CEO
 Chief Executive Officer - 15-05-31
More insiders

Quotes

Date Price Change Volume
24-05-26 14.82 +1.51% 23 400
24-05-24 14.6 +2.82% 491,200
24-05-23 14.2 -1.80% 35,800
24-05-22 14.46 -1.36% 74,600
24-05-21 14.66 -0.81% 138,400

Delayed Quote Hong Kong S.E., May 26, 2024 at 09:48 pm EDT

More quotes

Company Profile

ImmuneOnco Biopharmaceuticals Shanghai Inc is a China-based company mainly engaged in research and development of testing biotechnology. The Company's main businesses include the development of biotechnology for the systemic utilization of innate and adaptive immunity, and the development of next-generation tumor immunotherapies, which primarily focus on the adaptive immune system. The Company mainly operates its businesses in the domestic and overseas markets.
Sector
Biotechnology & Medical Research
More about the company

Income Statement Evolution

More financial data

Ratings for ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
13.53 CNY
Average target price
15.13 CNY
Spread / Average Target
+11.81%
Consensus

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
IMMUNEONCO BIOPHARMACEUTICALS (SHANGHAI) INC. Stock ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
-50.43% 699M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+12.30% 118B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+12.15% 106B
BIONTECH SE Stock BioNTech SE
-8.14% 23.4B
ARGENX SE Stock argenx SE
-1.69% 21.78B
GENMAB A/S Stock Genmab A/S
-10.60% 18.09B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.25% 16.72B
BEIGENE, LTD. Stock BeiGene, Ltd.
-15.33% 15.97B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.80% 14.03B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+28.03% 11.67B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 1541 Stock